Meningioma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• MEK 1
• BAP1 1
• CDK4/6 0
• MAPK 0
• MYC 0
• PARP 1

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

  NCT03173950· National Cancer Institute (NCI)· Updated 27 Oct 2026

  “Support was withdrawn from study resulting in early termination of study. Investigator had to close study due to no drug supply.”Registry text, quoted unchanged. Source

• Withdrawn

  Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC

  NCT04298541· Weill Medical College of Cornell University· Updated 31 Aug 2026

  “Funding has not been solidified for the initiation of the study.”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

  NCT05130866· Recursion Pharmaceuticals Inc.· Updated 17 Aug 2026

  “Study was terminated due to sponsor decision. This decision was not related to safety concerns with REC-2282.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of ONC201 for Refractory Meningioma

  NCT06012929· University of Nebraska· Updated 26 Jan 2026

  “Protocol not moving forward.”Registry text, quoted unchanged. Source

• Suspended

  68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma

  NCT07353229· Thomas Jefferson University· Updated 23 Jan 2026

  “dose escalation trial, and the first 3 patients (who made up a cohort) were all accrued”Registry text, quoted unchanged. Source

• Terminated

  MEningioma Detection Using Non Contrast MRI TecHniquEs

  NCT04113408· Fondation Ophtalmologique Adolphe de Rothschild· Updated 6 Jan 2026

  “The study was discontinued due to lack of inclusion.”Registry text, quoted unchanged. Source

• Terminated

  9-ING-41 in Pediatric Patients With Refractory Malignancies.

  NCT04239092· Actuate Therapeutics Inc.· Updated 17 Jul 2025

  “The decision to conclude study was made to optimize the clinical study design and protocol to further evaluate the safety profile of elraglusib (9-ING-41) in pediatric and adult patients with refractory Ewings Sarcoma.”Registry text, quoted unchanged. Source

• Terminated

  Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

  NCT03095248· Children's Hospital Medical Center, Cincinnati· Updated 22 Apr 2025

  “Results review of patient data”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

  NCT03604978· National Cancer Institute (NCI)· Source

• Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

  NCT04104529· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

  NCT04374305· Scott R. Plotkin, MD, PhD· Source

• Rare CNS Tumors Outcomes &Risk

  NCT03251989· National Cancer Institute (NCI)· Source

• A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

  NCT07533942· Jazz Pharmaceuticals· Source

• Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

  NCT03173950· National Cancer Institute (NCI)· Source

• Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

  NCT03180268· NRG Oncology· Source

• Comparing Radiation After Surgery to Observation After Surgery in Patients With Clinical Low-Risk, Molecular High-Risk Meningioma, and Evaluating Observation After Surgery in Patients With Clinical and Molecular Low-Risk Meningioma

  NCT07785687· NRG Oncology· Source

• 177Lu-DOTATATE for Recurrent Meningioma

  NCT06326190· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Multicenter Trial on Surgical Outcome and Quality of Life in Juxta-medullary Tumors

  NCT07056023· University Hospital Muenster· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.